258 related articles for article (PubMed ID: 34779401)
1. Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation.
Lin XT; Yu HQ; Fang L; Tan Y; Liu ZY; Wu D; Zhang J; Xiong HJ; Xie CM
Elife; 2021 Nov; 10():. PubMed ID: 34779401
[TBL] [Abstract][Full Text] [Related]
2. PLK1/NF-κB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression.
Tian L; Yao K; Liu K; Han B; Dong H; Zhao W; Jiang W; Qiu F; Qu L; Wu Z; Zhou B; Zhong M; Zhao J; Qiu X; Zhong L; Guo X; Shi T; Hong X; Lu S
Oncogene; 2020 Apr; 39(15):3145-3162. PubMed ID: 32060423
[TBL] [Abstract][Full Text] [Related]
3. In vivo analysis of FBXO45-mediated fibrosis and liver tumorigenesis in a chemically induced mouse model of hepatocellular carcinoma.
Zhang J; Lin XT; Fang L; Xie CM
STAR Protoc; 2023 Mar; 4(1):102124. PubMed ID: 36853700
[TBL] [Abstract][Full Text] [Related]
4. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1.
Shi W; Feng L; Dong S; Ning Z; Hua Y; Liu L; Chen Z; Meng Z
Cell Commun Signal; 2020 Jun; 18(1):100. PubMed ID: 32576198
[TBL] [Abstract][Full Text] [Related]
5. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
Zhang C; Wang X; Fang D; Xu P; Mo X; Hu C; Abdelatty A; Wang M; Xu H; Sun Q; Zhou G; She J; Xia J; Hui KM; Xia H
Theranostics; 2021; 11(5):2108-2122. PubMed ID: 33500714
[No Abstract] [Full Text] [Related]
6. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
Haupenthal J; Bihrer V; Korkusuz H; Kollmar O; Schmithals C; Kriener S; Engels K; Pleli T; Benz A; Canamero M; Longerich T; Kronenberger B; Richter S; Waidmann O; Vogl TJ; Zeuzem S; Piiper A
Neoplasia; 2012 May; 14(5):410-9. PubMed ID: 22745587
[TBL] [Abstract][Full Text] [Related]
7. Fbxo45 facilitates the malignant progression of breast cancer by targeting Bim for ubiquitination and degradation.
Zheng M; Wu L; Xiao R; Cai J; Chen W; Shen S
BMC Cancer; 2024 May; 24(1):619. PubMed ID: 38773471
[TBL] [Abstract][Full Text] [Related]
8. Fbxo45 promotes the malignant development of esophageal squamous cell carcinoma by targeting GGNBP2 for ubiquitination and degradation.
Wang Q; Wu L; Cao R; Gao J; Chai D; Qin Y; Ma L; Wu S; Tao Y; Ma J; Wang ZW
Oncogene; 2022 Oct; 41(43):4795-4807. PubMed ID: 36127399
[TBL] [Abstract][Full Text] [Related]
9. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
[TBL] [Abstract][Full Text] [Related]
10. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
11. Fbxo45 facilitates pancreatic carcinoma progression by targeting USP49 for ubiquitination and degradation.
Wu L; Yu K; Chen K; Zhu X; Yang Z; Wang Q; Gao J; Wang Y; Cao T; Xu H; Pan X; Wang L; Xia J; Li Y; Wang ZP; Ma J
Cell Death Dis; 2022 Mar; 13(3):231. PubMed ID: 35279684
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
[TBL] [Abstract][Full Text] [Related]
13. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
Mok WC; Wasser S; Tan T; Lim SG
World J Gastroenterol; 2012 Jul; 18(27):3527-36. PubMed ID: 22826617
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma.
Zhang J; Cheng J; Zeng Z; Wang Y; Li X; Xie Q; Jia J; Yan Y; Guo Z; Gao J; Yao M; Chen X; Lu F
Oncotarget; 2015 Dec; 6(39):42040-52. PubMed ID: 26547929
[TBL] [Abstract][Full Text] [Related]
15. Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice.
Lin XT; Zhang J; Liu ZY; Wu D; Fang L; Li CM; Yu HQ; Xie CM
Cell Rep; 2023 Jul; 42(7):112812. PubMed ID: 37450367
[TBL] [Abstract][Full Text] [Related]
16. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
Tu K; Yang W; Li C; Zheng X; Lu Z; Guo C; Yao Y; Liu Q
Mol Cancer; 2014 May; 13():110. PubMed ID: 24884509
[TBL] [Abstract][Full Text] [Related]
17. Hsa-let-7b inhibits cell proliferation by targeting PLK1 in HCC.
He Z; Deng W; Jiang B; Liu S; Tang M; Liu Y; Zhang J
Gene; 2018 Oct; 673():46-55. PubMed ID: 29913237
[TBL] [Abstract][Full Text] [Related]
18. Elevated FBXL18 promotes RPS15A ubiquitination and SMAD3 activation to drive HCC.
Yu HQ; Li F; Xiong H; Fang L; Zhang J; Bie P; Xie CM
Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37378633
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma.
Gutschner T; Hämmerle M; Pazaitis N; Bley N; Fiskin E; Uckelmann H; Heim A; Groβ M; Hofmann N; Geffers R; Skawran B; Longerich T; Breuhahn K; Schirmacher P; Mühleck B; Hüttelmaier S; Diederichs S
Hepatology; 2014 May; 59(5):1900-11. PubMed ID: 24395596
[TBL] [Abstract][Full Text] [Related]
20. CDK1-PLK1/SGOL2/ANLN pathway mediating abnormal cell division in cell cycle may be a critical process in hepatocellular carcinoma.
Li L; Huang K; Zhao H; Chen B; Ye Q; Yue J
Cell Cycle; 2020 May; 19(10):1236-1252. PubMed ID: 32275843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
